Breaking News Headlines Today | Ground News

See every side of every news story

swrankinnews.com image

News from swrankinnews.com

Pearl, United States

The Ground News media bias check for swrankinnews.com is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

swrankinnews.com’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about swrankinnews.com

Where is swrankinnews.com located?Pearl, United Statesswrankinnews.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top swrankinnews.com News

The Hong Kong Heroes: Unveiling Guangdong and Hong Kong's "La Grande Vadrouille" during WWII | Brothers in Arms (2)

Hong Kong City · Hong Kong

The Hong Kong Heroes: Unveiling Guangdong and Hong Kong's "La Grande Vadrouille" during WWII | Brothers in Arms (2)

54% Center coverage: 31 sources

GUANGZHOU, China, Sept. 9, 2025 /PRNewswire/ -- News report from GDToday: This Chinese force was honored by the U.S. President and had its representative decorated by the British Crown. They are the Hong Kong-Kowloon Independent Brigade of the Dongjiang (East…See the Story

Akeso (SEHK:9926) Unveils Promising Data For IO-Resistant Lung Cancer Therapy

Hong Kong City · Hong Kong

Akeso (SEHK:9926) Unveils Promising Data For IO-Resistant Lung Cancer Therapy

57% Center coverage: 30 sources

Akeso (SEHK:9926) recently captured attention by presenting promising data on its cadonilimab therapy at the World Conference on Lung Cancer, highlighting its potential as a breakthrough treatment for immunotherapy-resistant non-small cell lung cancer. Over the last quarter, the company's share price surged 40%, potentially influenced by these significant clinical developments and the awarding of Breakthrough Therapy Designation. The broader mar…See the Story

ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders

Suzhou, China · Suzhou

ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders

57% Center coverage: 28 sources

SUZHOU, China, Sept. 9, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company") recently announced that its lead engineered exosome candidate, MVR-EX105 ("EX105") is featured in a poster presentation at the 2025 Annual Congress of the International Federation for the…See the Story

Breaking News Topics Related to swrankinnews.com